Solanezumab's Impact on Beta-Amyloid and Cognitive Decline in Alzheimer's Disease Management
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on October 20th, 2023
|
The accumulation of defective beta-amyloid in the brain of patients with Alzheimer’s disease interferes with neurotransmission and leads to the clinical manifestations associated with the condition. Thus, clearance of these beta-amyloid plaques can potentially revert the symptoms. Thus, the National Institute on Aging had sponsored a study to investigate the effect of solanezumab in managing Alzheimer’s disease.
This phase 3 clinical trial involved 1169 participants aged 65 to 85 diagnosed with preclinical Alzheimer's disease without dementia or cognitive impairment, confirmed through PET scans showing beta-amyloid plaque accumulation. Participants were randomly assigned to receive either a placebo or 1600 mg of solanezumab intravenously every 4 weeks. After 240 weeks of treatment, the researchers found that solanezumab did not reduce the rate of cognitive decline, as measured by the Preclinical Alzheimer Cognitive Composite score. However, PET scans revealed lower beta-amyloid levels in those treated with solanezumab. This finding contrasts with existing literature, where a previous study using a lower dose of 400 mg every 4 weeks produced clinically significant benefits. This discrepancy may be explained by the possibility that the high solanezumab dose caused excessive beta-amyloid depletion required for normal cognitive function.
This phase 3 clinical trial involved 1169 participants aged 65 to 85 diagnosed with preclinical Alzheimer's disease without dementia or cognitive impairment, confirmed through PET scans showing beta-amyloid plaque accumulation. Participants were randomly assigned to receive either a placebo or 1600 mg of solanezumab intravenously every 4 weeks. After 240 weeks of treatment, the researchers found that solanezumab did not reduce the rate of cognitive decline, as measured by the Preclinical Alzheimer Cognitive Composite score. However, PET scans revealed lower beta-amyloid levels in those treated with solanezumab. This finding contrasts with existing literature, where a previous study using a lower dose of 400 mg every 4 weeks produced clinically significant benefits. This discrepancy may be explained by the possibility that the high solanezumab dose caused excessive beta-amyloid depletion required for normal cognitive function.